Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Is high-risk BCR really mHSPC?? Live webinar replay

1:30:59
 
Share
 

Manage episode 519564519 series 3350113
Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

We recently hosted another live webinar for our Gold Partners, Mundipharma, this time asking the question, "Is high-risk BCR actually metastatic prostate cancer??". It's a reasonable question! This podcast was anchored from the GU Cast studio in Melbourne by usual hosts, Renu Eapen and Declan Murphy, joined in person by Andrew Loblaw, radiation oncologist from Toronto, and online by medical oncologist Jeff Goh in Brisbane.

Best enjoyed on our YouTube channel if you want to check out the slides.
Runsheet:

  • Is high-risk biochemical recurrence already metastatic prostate cancer?Declan Murphy
  • Is the management of high-risk BCR and mHSPC now the same? Jeffrey Goh
  • Prostate radiotherapy is the real triplet therapy; plus when should we use SBRT? Andrew Loblaw

Q&A and case discussions
This webinar was organised by our Gold Partners, Mundipharma, who also support GU Cast as Gold Partners through an unrestricted educational grant.

  continue reading

212 episodes

Artwork
iconShare
 
Manage episode 519564519 series 3350113
Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

We recently hosted another live webinar for our Gold Partners, Mundipharma, this time asking the question, "Is high-risk BCR actually metastatic prostate cancer??". It's a reasonable question! This podcast was anchored from the GU Cast studio in Melbourne by usual hosts, Renu Eapen and Declan Murphy, joined in person by Andrew Loblaw, radiation oncologist from Toronto, and online by medical oncologist Jeff Goh in Brisbane.

Best enjoyed on our YouTube channel if you want to check out the slides.
Runsheet:

  • Is high-risk biochemical recurrence already metastatic prostate cancer?Declan Murphy
  • Is the management of high-risk BCR and mHSPC now the same? Jeffrey Goh
  • Prostate radiotherapy is the real triplet therapy; plus when should we use SBRT? Andrew Loblaw

Q&A and case discussions
This webinar was organised by our Gold Partners, Mundipharma, who also support GU Cast as Gold Partners through an unrestricted educational grant.

  continue reading

212 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play